This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn).
Patents
Revelle Aesthetics is committed to protecting its innovations through its effort in securing patent protection in the United States and other territories internationally.
Virtual Patent Marking
Pursuant to 35 U.S.C. § 287(a) regarding patent law, the following provides notice of Revelle Aesthetics’ rights in the below identified United States Patents, and their foreign counterparts, and are listed in relation to the product name. Additional U.S. and Non-U.S. patent applications may be pending.
The following list is not exhaustive, and other components not listed here may be protected by one or more patents in the United States and elsewhere. Components of the item listed below may be sold individually or as part of a combination product. Other components not listed herein may have patent markings placed on the particular product or packaging to provide adequate notice of its patent protection.
Avéli® Precision Cellulite Release Device
United States Patents
11013527, 11116888, D1013173
International Registered Design Nos.
AU202211759, DM222657
Other U.S. and International patents pending.
Avéli® is indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating treatment benefits through one year of observation. The most common side effects reported were mild pain within the first 24 hours and bruising and tenderness to the touch which typically resolved within 30 days. Some patients returned to normal activities within one day of the procedure and most within a week. As with any medical procedure, there are risks associated with the procedure. Consult with your physician for full safety information.